MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$75,228K
EPS
-$0.71
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Collaboration revenue
0
17,851*
2,764
11,476
Impairment of long-lived assets
0
-1,927*
3,855
0
Research and development
98,162
87,844*
74,094
78,388
General and administrative
20,357
15,716*
17,336
17,645
Total operating expenses
118,519
101,632*
95,285
96,033
Loss from operations
-84,154
-83,781*
-92,521
-84,557
Interest and other income
14,981
10,676*
10,444
8,051
Interest and other expense
61
61*
98
108
Total other income
14,920
10,615*
10,346
7,943
Net loss
-69,234
-73,167*
-82,175
-76,614
Unrealized gain on marketable securities
-5,994
947*
1,222
337
Total comprehensive loss
-75,228
-72,221
-80,953
-76,277
Basic EPS
-0.71
-0.843
-0.94
-0.95
Diluted EPS
-0.71
-0.843
-0.94
-0.95
Basic Average Shares
97,534,269
85,722,064
87,300,286
80,449,405
Diluted Average Shares
97,534,269
85,722,064
87,300,286
80,449,405
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Total comprehensive
loss
-$75,228K
Interest and other income
$14,981K
Net loss
-$69,234K
Unrealized gain on
marketable securities
-$5,994K
Total other income
$14,920K
Interest and other
expense
$61K
Loss from operations
-$84,154K
something is missing
$34,365K
Total operating
expenses
$118,519K
Research and development
$98,162K
General and
administrative
$20,357K
Buy us a coffee
Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (KYMR)